FDA-approved
Hormones & metabolism
Pasireotide
Evidence
FDA approved
Class
Somatostatin analog
KEY TAKEAWAY
Pasireotide is a synthetic cyclic peptide that binds several somatostatin receptor subtypes. It is sold as Signifor. The FDA approved pasireotide (Signifor) in 2012 for Cushing's disease, and a long-acting form (Signifor LAR) in 2014 for acromegaly.
Written by the Veylo editorial team · Updated
November 2026
What it is
Somatostatin analog
Approved for
Cushing's disease and acromegaly
Key fact
The FDA approved pasireotide (Signifor) in 2012 for Cushing's disease, and a long-acting form (Signifor LAR) in 2014 for acromegaly.
Route
Subcutaneous injection, or a monthly injection into muscle
Evidence strength
FDA approved
Pasireotide is a synthetic cyclic peptide that binds several somatostatin receptor subtypes. It is sold as Signifor.
It lowers the release of ACTH and growth hormone from pituitary tumors.
The FDA approved pasireotide (Signifor) in 2012 for Cushing's disease, and a long-acting form (Signifor LAR) in 2014 for acromegaly.
Cushing's disease and acromegaly.
High blood sugar is very common and can be significant. Gallstones, diarrhea and a slow heart rate are also reported.
U.S. FDA prescribing information for Pasireotide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.